[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Louisiana State University Health Sciences Center Shreveport\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":129},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,44,69,101],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100643648","ankle-brachial-index-changes-post-exercise-and-its-effects-on-patient-centered-outcomes-and-gait-100643648",false,"NCT07637396","Ankle-Brachial Index Changes Post Exercise and Its Effects on Patient-Centered Outcomes and Gait","Exercise-Induced Ankle-Brachial Index Dynamics as a Predictive Marker in Peripheral Arterial Disease","ExerciseABI","Inclusion Criteria\n\n* individuals over 65 years of age\n* individuals aged 50-64 with a risk factor for atherosclerosis including diabetes mellitus, history of smoking, hyperlipidemia, hypertension, or family history of peripheral arterial disease (PAD)\n* individuals aged 18-50 with diabetes mellitus and one additional risk factor for atherosclerosis as noted above, or\n* individuals with known atherosclerotic disease in another vascular bed including the coronary, carotid, subclavian, renal, or mesenteric artery stenosis, and individuals with known PAD\n\nExclusion Criteria\n\n* contraindications to brachial and\u002For ankle pressure measurement including history of deep vein thrombosis\n* lymphedema of the arms or legs\n* history of mastectomy or current leg ulceration preventing placement of a blood pressure cuff around the lower leg\n* an inability to lie in a supine position for 15 min\n* self-reported inability to walk for 6 minutes\n* severe cardiac or pulmonary disease limiting exercise\n* inability to obtain a Dopplerable pulse\n* noncompressible arteries (ABI \\>1.4)\n* those unable to consent",true,"ALL","18 Years",{"count":21,"type":22},85,"ESTIMATED","OBSERVATIONAL","The goal of this observational study or clinical trial is to investigate how exercise can affect different areas of a person's life, especially those people with vascular disease. This is important because exercise can be beneficial for people with vascular disease. The study could include any of the following: those aged 65 years of age and older, between the ages of 50-64 who smokes, has diabetes, high blood pressure, high cholesterol, or has a family member with vascular disease, between the ages of 18-49 with diabetes and one other factor listed above, or those with vascular disease. The main question\\[s\\] it aims to answer is if exercise testing can better predict vascular disease.\n\nThe following research questions will be addressed in this study:\n\n1. Does baseline ABI influence the magnitude and recovery trajectory of ABI following an acute bout of exercise across a spectrum of vascular function?\n2. What association does exercise-induced ABI changes have on patient-reported outcomes of quality of life and intermittent claudication?\n3. Do functional outcomes of gait speed, time to claudication, gait variables related to rest breaks in 6MWT, and walking distance predict the magnitude of exercise-induced ABI reduction?\n\nParticipants will :\n\n* complete various questionnaires and a routine screening for vascular disease \\*walk for 6 minutes at your own pace\n* additional vascular screening tests will be performed.",[26],"Peripheral Arterial Disease(PAD)",[28,29,30],"peripheral arterial disease","ankle brachial index","doppler ultrasound","NOT_YET_RECRUITING","2026-06-04",{"date":34,"type":35},"2026-06-09","ACTUAL",{"date":37,"type":22},"2026-06",{"date":39,"type":22},"2028-01",{"name":41,"class":42},"Louisiana State University Health Sciences Center Shreveport","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":54,"phases":55,"briefSummary":57,"conditions":58,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":43},"100637606","impact-of-heat-on-dual-task-performance-100637606","NCT07629414","Impact of Heat on Dual Task Performance","Impact of Heat Stress and Fatigue on Dual Task Performance-A Pilot Study.","Inclusion Criteria:\n\n* health via PARQ+\n\nExclusion Criteria:\n\n* inability to safely swallow core temperature pill\n* musculoskeletal injury in past 3 months\n* diagnosed concussion or vestibular disorder\n* known pregnancy","57 Years",{"count":53,"type":22},10,"INTERVENTIONAL",[56],"NA","This study looks at how people response performing single and dual tasks (cognitive and motor) prior to and after a rapid heat stress that increased core temperature to 39C.",[59,60],"Healthy","Heat Stress, Exertional","RECRUITING",{"date":63,"type":35},"2026-06-05",{"date":65,"type":35},"2024-10-09",{"date":67,"type":22},"2026-08",{"name":41,"class":42},{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":73,"acronym":74,"eligibilityCriteria":75,"healthyVolunteers":11,"sex":76,"minAge":77,"maxAge":78,"enrollmentInfo":79,"targetDuration":4,"studyType":54,"phases":81,"briefSummary":82,"conditions":83,"keywords":87,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":4},"100563554","transcutaneous-tibial-nerve-stimulation-for-overactive-bladder-syndrome-and-associated-gait-changes-in-post-menopausal-women-100563554","NCT06617676","Transcutaneous Tibial Nerve Stimulation for Overactive Bladder Syndrome and Associated Gait Changes in Post-menopausal Women","TTNS","Inclusion Criteria: Inclusion criteria include females over 60 years of age who score an 8 or greater on the OAB-V8 with no exclusion criteria.\n\n\\-\n\nExclusion Criteria: those who experience stress UI only, have a pacemaker, neurologic deficit (e.g. Parkinson\\'s disease, multiple sclerosis, spinal cord injury), current urinary tract infection, known active cancer, or current OAB medication use (Tolterdine, etc.) with consideration of a washout period, and inability to walk 30 meters.\n\n\\-","FEMALE","60 Years","85 Years",{"count":80,"type":22},60,[56],"The goal of this clinical trial is to learn if surface tibial electrical stimulation (mild electrical signals on the inside of the ankle) helps women 60 years or older with urine leakage that happens on the way to the bathroom or at night time. The main questions it aims to answer are: 1). How many treatments per week over a 12-week period improve a person\\'s bladder symptoms?; 2). Is a person more confident that they will not fall and \u002F or leak urine on the way to the bathroom after the treatment with the electrical stimulation treatments; 3). Does the way a person walks when they need to go to the bathroom change after they have had the electrical stimulation? They will visit the clinic 3 times to complete several questionnaires and walk with a full bladder and empty bladder. On the first visit, the participant will be taught how to use the electrical stimulation device. Participants will either receive the treatment 2 or 4 times per week for 12 weeks or no treatment with the option to receive treatment following the 12 weeks. Participants will be given a bladder diary to complete at the start of treatment, at 6 weeks, then at 12 weeks and will be instructed in completion. They will drink water until they have a strong urge to urinate, then will walk along an electronic pathway and will go empty their bladder. After emptying, they will walk back along the electronic pathway again. They will also complete a Timed Up and Go test - stand up from a chair, walk 3 meters, then turn around, walk back, then sit down. At the 6th week follow up and the 12th week follow up, they will complete each questionnaire again and complete the walking tasks again.",[84,85,86],"Overactive Bladder Syndrome","Urinary Incontinence, Urge","Nocturia",[88,89,90,91,92,86],"Overactive bladder syndrome","Transcutaneous sacral nerve stimulation","Falls","Urinary urgency","Urinary frequency","2024-09-26",{"date":95,"type":35},"2024-09-27",{"date":97,"type":22},"2024-10",{"date":99,"type":22},"2026-03",{"name":41,"class":42},{"id":102,"slug":103,"hasResults":11,"nctId":104,"briefTitle":105,"officialTitle":105,"acronym":4,"eligibilityCriteria":106,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":107,"enrollmentInfo":108,"targetDuration":4,"studyType":54,"phases":110,"briefSummary":112,"conditions":113,"keywords":117,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":43},"100553166","phase-3-lumateperone-for-the-improvement-of-apathy-in-patients-with-psychotic-symptoms-100553166","NCT06482554","Lumateperone for the Improvement of Apathy in Patients With Psychotic Symptoms.","Inclusion Criteria:\n\n* Male or female subjects between the ages of 18-65 that have been diagnosed with Schizophrenia, Schizoaffective Disorder or Schizophrenia Spectrum and Other Psychotic Disorders.\n* A BPRS score \\> 35 at the screening visit.\n* An AES-C score \\> 32 at the screening visit.\n* If the subject is on a therapeutic regimen, that regimen must be stable for at least 30 days prior to screening. A therapeutic regimen may include medication, supplements, and\u002For probiotics.\n* In the opinion of the Investigator, the subject is able to participate in all scheduled evaluations, and likely to be compliant and complete all required assessments.\n* Female subjects of childbearing potential must not be pregnant or breast-feeding. Female subjects of childbearing potential must have a negative urine pregnancy test. Subjects of childbearing or child-fathering potential must be willing to use medically acceptable forms of birth control, which includes abstinence, while being treated on this study and for 30 days after the last dose of study drug.\n* Must speak and understand English, as the consent and all evaluations will be conducted in English.\n* Must be willing to take and pass a urine drug screen with a negative result in order to rule out psychotic symptoms due to drugs of abuse.\n\nExclusion Criteria:\n\n* A BPRS score \\\u003C 35 at the screening visit.\n* An AES-C score \\\u003C 32 at the screening visit.\n* Have any clinically significant medical condition or an unstable intercurrent illness that would, in the opinion of the Investigator, preclude study participation.\n* Are currently taking more than one antipsychotic medication.\n* Are currently taking a long-acting injectable medication for psychotic symptoms.\n* Have a substance use disorder or show a positive drug screen for stimulants.\n* Are pregnant or of female sex with no evidence of measures for pregnancy prevention.\n* Presence of dementia.\n* Intellectual disability or cognitive impairment that would affect the symptom\u002Fapathy assessments, in the view of the investigator.\n* A diagnosis of Parkinson's disease.","65 Years",{"count":109,"type":22},80,[111],"PHASE3","This study is looking to determine if Lumateperone improves motivation in patients with schizophrenia or schizoaffective disorders who show high levels of apathy as judged by AES-C-Apathy (Apathy Evaluation Scale - Clinician - Apathy) assessment and to examine a possible correlation between improvement in apathy scores and changes in elements of the PANSS (Positive and Negative Syndrome Scale) due to treatment with Lumateperone.",[114,115,116],"Apathy","Schizophrenia","Schizophrenia; Psychosis",[115,118,119,120],"Schizoaffective","Psychosis","Psychotic","2024-06-26",{"date":123,"type":35},"2024-07-01",{"date":125,"type":22},"2024-06",{"date":127,"type":22},"2026-12",{"name":41,"class":42},""]